文献速递炎症性肠病

抗MAdCAM抗体PF-00547659治疗克罗恩病的II期评估:OPERA研究

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
PubMed 文献 · Gut · 2017-10-05

OPERA研究为II期随机双盲安慰剂对照试验,纳入265例中重度克罗恩病患者,随机接受PF-00547659 22.5 mg、75 mg、225 mg或安慰剂。第8或12周时CDAI-70应答率在安慰剂与PF-00547659组间无显著差异,但高基线C反应蛋白患者缓解率更高;药物显示药理学活性,无安全性信号。

要点

  • II期OPERA研究未观察到PF-00547659与安慰剂在CDAI-70应答上的统计学显著差异。
  • PF-00547659治疗组可溶性MAdCAM呈剂量相关持续下降,循环β7+中央记忆T细胞呈剂量相关增加。
  • 研究期间未观察到安全性信号。

核心结论

  • 在中重度克罗恩病患者中,PF-00547659与安慰剂之间的临床终点差异未达统计学显著。
  • PF-00547659具有药理学活性,表现为可溶性MAdCAM持续剂量相关下降及循环β7+中央记忆T细胞剂量相关增加。

研究设计与样本

  • II期随机双盲安慰剂对照临床试验。
  • 纳入年龄18-75岁、中重度活动性克罗恩病(CDAI 220-450)、对肿瘤坏死因子拮抗剂和/或免疫抑制剂治疗失败或不耐受、高敏C反应蛋白>3.0 mg/L且结肠镜见溃疡的成人患者。
  • 患者随机接受PF-00547659 22.5 mg、75 mg、225 mg或安慰剂。
  • 主要终点为第8或12周CDAI较基线下降70分(CDAI-70)。
  • 共265例患者符合研究入组条件。

主要发现

  • 第8或12周时,安慰剂组与PF-00547659组CDAI-70应答无显著差异。
  • 基线C反应蛋白较高的患者缓解率更高(>5 mg/L vs >18.8 mg/L)。
  • PF-00547659治疗组可溶性MAdCAM从基线至第2周呈剂量相关显著下降,并在研究期间保持低水平。
  • 第8和12周时,PF-00547659治疗组循环β7+ CD4+中央记忆T淋巴细胞增加。
  • 未观察到安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This phase II, randomised, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule (MAdCAM) to selectively reduce lymphocyte homing to the intestinal tract, in patients with moderate-to-severe Crohn's disease (CD). DESIGN: Eligible adults were aged 18-75 years, with active moderate-to-severe CD (Crohn's Disease Activity Index (CDAI) 220-450), a history of failure or intolerance to antitumour necrosis factor and/or immunosuppressive agents, high-sensitivity C reactive protein >3.0 mg/L and ulcers on colonoscopy. Patients were randomised to PF-00547659 22.5 mg, 75 mg or 225 mg or placebo. The primary endpoint was CDAI 70-point decrease from baseline (CDAI-70) at week 8 or 12. RESULTS: In all, 265 patients were eligible for study entry. Although CDAI-70 response was not significantly different with placebo versus PF-00547659 treatment at weeks 8 or 12, remission rate was greater in patients with higher baseline C reactive protein (>5 mg/L vs >18.8 mg/L, respectively). Soluble MAdCAM decreased significantly from baseline to week 2 in a dose-related manner and remained low during the study in PF-00547659-treated patients. Circulating β7+ CD4+ central memory T-lymphocytes increased at weeks 8 and 12 with PF-00547659 treatment. No safety signal was seen. CONCLUSIONS: Clinical endpoint differences between PF-00547659 and placebo did not reach statistical significance in patients with moderate-to-severe CD. PF-00547659 was pharmacologically active, as shown by a sustained dose-related decrease in soluble MAdCAM and a dose-related increase in circulating β7+ central memory T cells. TRIAL REGISTRATION NUMBER: NCT01276509; Results.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Lee SD, Tarabar D, et al. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2017. PMID: 28982740. doi:10.1136/gutjnl-2016-313457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。